S. K. Lanjhiyana and Sweety Lanjhiyana
Accepted Abstracts: Biochem & Pharmacol
Lymphatic filariasis is considered endemic especially in tropical and subtropical regions of developing countries. More than 120 million populations around the world are infected whereas more than one billion people at risk of infection. Recommended combination therapies of broad-spectrum doses of either ivermectin with albendazole or albendazole with diethylcarbamazine are potential for microfilaricides only but having no effect on the adult macroflariae. Hence, it is essential to develop and effective phyto-medicine based antifilarial drug having potential to kill or permanently sterilize the adult worm with comparatively no side effect on other hand. Dried chopped leaves of Lawsonia inermis (Family: Lythraceae) were subjected to soxhletion for methanolic (MLE) and aqueous (ALE) extracts. The bio-assay guided fractions of MLE & ALE obtained after column chromatography was subjected to in-vitro screening for worm motility and nerve muscle preparation assay against adult bovine filarial S. digitata parasite. After incubation for 24 and 48 h respectively at dose concentration of 0.01 to 1.0 mg/ml for possible dose response relationship thereby confirmed for irreversible-paralysis of both male and female worms was found to be significant (P<0.05) effect. Present study was focused to explore possible phyto-fractions based macrofilaricidal drug for treatment of human filariasis by using in-vitro and thereafter for in-vivo screening methodology.
